Nuvectis Pharma (NVCT) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NVCT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Nuvectis Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.63 |
| 52 Week High | US$29.28 |
| 52 Week Low | US$5.55 |
| Beta | -0.25 |
| 1 Month Change | 105.77% |
| 3 Month Change | 147.54% |
| 1 Year Change | 150.06% |
| 3 Year Change | 21.55% |
| 5 Year Change | n/a |
| Change since IPO | 504.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -31.2% | 4.1% | 1.6% |
| 1Y | 150.1% | 41.1% | 18.6% |
Return vs Industry: NVCT exceeded the US Biotechs industry which returned 41.1% over the past year.
Return vs Market: NVCT exceeded the US Market which returned 18.6% over the past year.
Price Volatility
| NVCT volatility | |
|---|---|
| NVCT Average Weekly Movement | 19.1% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NVCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVCT's weekly volatility has increased from 12% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 12 | Ron Bentsur | www.nuvectis.com |
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.
Nuvectis Pharma, Inc. Fundamentals Summary
| NVCT fundamental statistics | |
|---|---|
| Market cap | US$616.95m |
| Earnings (TTM) | -US$29.59m |
| Revenue (TTM) | n/a |
Is NVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.59m |
| Earnings | -US$29.59m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 22:26 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nuvectis Pharma, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |
| Christopher Liu | Lucid Capital Markets |